Retatrutide 10mg
Retatrutide is a novel, synthetic multi-receptor peptide agonist that activates the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.
This triagonist profile positions Retatrutide as a promising agent for the investigation of weight management, glucose regulation, insulin sensitivity, and metabolic disorders.
Preclinical and clinical research indicates that Retatrutide may support significant body fat reduction, improved glycemic control, and enhanced energy expenditure due to its comprehensive receptor activation mechanism. It is being studied as a next-generation therapeutic peptide in the context of obesity, Type 2 Diabetes, and related metabolic dysfunctions.
Intended for laboratory research use only. Not for human or veterinary use.
Recommended Reconstitution Method:
Preparation:
Allow the vial to reach room temperature before opening to avoid condensation.
Use aseptic techniques to prevent contamination.
Reconstitution:
Add bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection (SWFI).
Suggested concentration: Reconstitute 1 mg of Retatrutide with 1 mL of bacteriostatic water for a final concentration of 1 mg/mL. Adjust volume for desired concentration.
Mixing:
Gently swirl (do not shake) the vial until the powder is fully dissolved and the solution is clear. Avoid vigorous agitation to maintain peptide integrity.
Storage After Reconstitution:
Store reconstituted Retatrutide at 2–8°C (refrigerator).
Use within 14–30 days depending on solvent used and lab protocols. Discard if discoloration or particulate matter is present.
For Research Purposes Only
Retatrutide is a novel, synthetic multi-receptor peptide agonist that activates the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.
This triagonist profile positions Retatrutide as a promising agent for the investigation of weight management, glucose regulation, insulin sensitivity, and metabolic disorders.
Preclinical and clinical research indicates that Retatrutide may support significant body fat reduction, improved glycemic control, and enhanced energy expenditure due to its comprehensive receptor activation mechanism. It is being studied as a next-generation therapeutic peptide in the context of obesity, Type 2 Diabetes, and related metabolic dysfunctions.
Intended for laboratory research use only. Not for human or veterinary use.
Recommended Reconstitution Method:
Preparation:
Allow the vial to reach room temperature before opening to avoid condensation.
Use aseptic techniques to prevent contamination.
Reconstitution:
Add bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection (SWFI).
Suggested concentration: Reconstitute 1 mg of Retatrutide with 1 mL of bacteriostatic water for a final concentration of 1 mg/mL. Adjust volume for desired concentration.
Mixing:
Gently swirl (do not shake) the vial until the powder is fully dissolved and the solution is clear. Avoid vigorous agitation to maintain peptide integrity.
Storage After Reconstitution:
Store reconstituted Retatrutide at 2–8°C (refrigerator).
Use within 14–30 days depending on solvent used and lab protocols. Discard if discoloration or particulate matter is present.
For Research Purposes Only
Retatrutide is a novel, synthetic multi-receptor peptide agonist that activates the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.
This triagonist profile positions Retatrutide as a promising agent for the investigation of weight management, glucose regulation, insulin sensitivity, and metabolic disorders.
Preclinical and clinical research indicates that Retatrutide may support significant body fat reduction, improved glycemic control, and enhanced energy expenditure due to its comprehensive receptor activation mechanism. It is being studied as a next-generation therapeutic peptide in the context of obesity, Type 2 Diabetes, and related metabolic dysfunctions.
Intended for laboratory research use only. Not for human or veterinary use.
Recommended Reconstitution Method:
Preparation:
Allow the vial to reach room temperature before opening to avoid condensation.
Use aseptic techniques to prevent contamination.
Reconstitution:
Add bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection (SWFI).
Suggested concentration: Reconstitute 1 mg of Retatrutide with 1 mL of bacteriostatic water for a final concentration of 1 mg/mL. Adjust volume for desired concentration.
Mixing:
Gently swirl (do not shake) the vial until the powder is fully dissolved and the solution is clear. Avoid vigorous agitation to maintain peptide integrity.
Storage After Reconstitution:
Store reconstituted Retatrutide at 2–8°C (refrigerator).
Use within 14–30 days depending on solvent used and lab protocols. Discard if discoloration or particulate matter is present.
For Research Purposes Only